Based on the results of NALA trial, in February 2020, neratinib was approved by the US FDA with the expansion of the scope of application to be in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive BC who have received two or more prior anti-HER2 regimens. The gene discussed is ERBB2; the disease is breast cancer.